CGTN: China Outlines Four-point Proposal for the Future of APEC
21.11.2020 19:05:00 EET | Business Wire | Press release
With the world and the Asia-Pacific region undergoing profound changes, China has called for joint efforts to build an Asia-Pacific community with a shared future featuring openness, inclusiveness, innovation-driven growth, greater connectivity, and mutually beneficial cooperation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201121005045/en/
Read the original article here.
China highly values the role of the Asia-Pacific Economic Cooperation (APEC) and will continue to support the development of the organization, President Xi Jinping said on Friday when addressing the APEC Economic Leaders' Meeting in Beijing via video link.
Established in 1989, APEC has become an important platform to facilitate economic cooperation among 21 economies in the Asia-Pacific region.
However, the region is currently facing challenges such as backlashes against economic globalization, rising unilateralism, and protectionism, as well as the fallout from the COVID-19 pandemic.
"For the first time in decades, the Asia-Pacific as a whole registered negative economic growth," Xi said. "Protecting people's health and reviving the economy are two formidable tasks we have to take on."
The Chinese president outlined a four-point proposal for the future of Asia-Pacific cooperation.
Read more:
Foreign leaders urge APEC members to advocate multilateral trade
Open and inclusive
"First, we need to stay open and inclusive," Xi said. "It is important that the Asia-Pacific should remain the bellwether in safeguarding peace and stability, upholding multilateralism, and fostering an open world economy."
He called for further efforts to promote regional economic integration for the early realization of a Free Trade Area of the Asia-Pacific (FTAAP).
The FTAAP proposal was initiated in 2004 and written into the declaration of the APEC meeting in 2006. During the 2014 APEC meeting in Beijing, the initiative made a breakthrough, with APEC members unanimously adopting the FTAAP Beijing Roadmap to achieve the goal.
The recent signing of the Regional Comprehensive Economic Partnership (RCEP) free trade agreement was viewed as a significant step toward the establishment of the FTAAP.
The pact was signed on Sunday among its 15 participating countries, including the 10 member countries of the Association of Southeast Asian Nations and China, Japan, South Korea, Australia, and New Zealand.
"China welcomes the signing of the RCEP and will favorably consider joining the Comprehensive and Progressive Agreement for Trans-Pacific Partnership (CPTPP)," Xi said.
Effective since December 30, 2018, the CPTPP is a trade pact among 11 countries, including Japan, Canada, Australia, Singapore, Chile, and Mexico, whose aggregate gross domestic product accounts for 13 percent of the world economy.
Efforts should be made to "promote free and open trade and investment, and make economic globalization more open, inclusive, balanced and beneficial to all," he said.
Innovation-driven growth
"Second, we need to pursue innovation-driven growth," Xi said, calling for improving the digital infrastructure and bridging the digital divide in the region.
Asia-Pacific economies should "foster an open, fair, equitable and non-discriminatory environment for businesses," he stressed.
Digital technologies should play a bigger role in facilitating experience sharing on epidemic control, boosting economic recovery, and eradicating poverty in the region, he suggested.
The emphasis on innovation is in line with China's own priorities on development. The country vows to uphold the central role of innovation in its modernization drive and take self-reliance in science and technology as a strategic underpinning for national development, according to a newly unveiled blueprint for its development in the next 15 years.
"Third, we need to enhance connectivity," Xi added, calling connectivity a "vital basis of regional economic integration."
He pledged active efforts to set up "green lanes" with other parties to help make customs clearance more efficient during the pandemic and stabilize industrial and supply chains in the region and beyond.
The Chinese president also expressed the hope to work with other parties to build a high-quality Belt and Road.
Not a 'zero-sum political game'
"Fourth, we need to promote mutually beneficial cooperation," he said, stressing that economies in the region are highly complementary to each other.
"Our economic cooperation has never been a zero-sum political game in which one's loss is another's gain," he said. "Rather, our cooperation has provided us with a development platform to ensure what we each do can be mutually reinforcing and beneficial to all."
Xi called for advancing research of the development of COVID-19 vaccines and make them a global public good affordable in developing countries.
At the virtual meeting hosted by Malaysia, APEC launched a Post-2020 vision – the APEC Putrajaya Vision 2040, which is the bloc's new long-term blueprint for future cooperation. It laid out three economic drivers: "trade and investment," "innovation and digitalization," and "strong, balanced, secure, sustainable and inclusive growth."
The 2020 Kuala Lumpur Declaration was also issued at the meeting, calling for solidarity to defeat the pandemic and revive the economy across the region.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201121005045/en/
Contact information
Media:
Jiang Simin
jiang.simin@cgtn.com
+86 18826553286
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
